Selective estrogen receptor modulators: A new category of compounds to extend postmenopausal women's health

International Journal of Fertility and Women's Medicine

Volumn 44, Issue 5, 1999, Pages 221-226

  Goldstein, Steven R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical studies; Raloxifene; Tamoxifen

Indexed keywords

ANTIESTROGEN; DROLOXIFENE; ESTROGEN RECEPTOR; FULVESTRANT; MIPROXIFENE PHOSPHATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PLACEBO; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

BONE METABOLISM; BREAST CANCER; CLINICAL TRIAL; DRUG SELECTIVITY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN ACTIVITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

BONE DENSITY; BREAST NEOPLASMS; CHOLESTYRAMINE; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HIP FRACTURES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 0032738824     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. National Osteoporosis Foundation: Boning Up on Osteoporosis: A Guide to Prevention and Treatment. Washington, D., National Osteoporosis Foundation, 1991.
2. Jensen GF, Christiansen C, Boesen J, et al: Epidemiology of post-menopausal osteoporosis. J Orthopaed Res Register 166:75-81, 1982.
3. Stevenson JC, Whitehead MI: Postmenopausal osteoporosis. Br Med J 285:585-588, 1982.
4. Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. N Engl J Med 329:247-251, 1993.
5. Ravnikar V: Compliance with hormone therapy. Am J Obstet Gynecol 156:1332-1334, 1987.
6. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al: Estrogen replacement therapy: a ten year prospective study in the relationship to osteoporosis. Obstet Gynecol 53:277-281, 1979.
7. Genant HK, Baylink DJ, Gallagher JC: Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 161:1842-1846, 1989.
8. Criqui MH, Suarez L, Barrett-Connor E, et al: Postmenopausal estrogen use and mortality. Am J Epidemol 128:606-614, 1988.
9. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow up from the nurses' health study. N Engl J Med 325:756-762, 1991.
10. Beresford SA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349:458-461, 1997.
11. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995.
12. Gradishar WJ, Jordan CC: Clinical potential of new antiestrogens. J Clin Oncol 15:840-852, 1997.
13. Early Breast Cancer Trialists Collaborative Group: Effects of tamoxifen and of cytoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681, 1988.
14. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856, 1992.
15. Bagdad JD, Wolter J, Subbaiah PV, et al: Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70:1132-1135, 1990.
16. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri. [Letter] Lancet 2:563, 1988.
17. Jordan VC. Tamoxifen and endometrial cancer (Letter). Lancet 1:375-376, 1989.
18. Mathew A, Chabon AB, Kabakow B, et al: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY J Med 90:207-208, 1990.
19. Atlanta G, Pozzi M, Vincenzoni C, et al: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37:378-380, 1990.
20. Neven P, Muylder X, Van Belle Y, et al: Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Reprod Biol 35:235-238, 1990.
21. Gal D, Kopel S, Bashevkin M, et al: Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer-preliminary report. Gynecol Oncol 42:120-123, 1991.
22. Schwartz LB, Snyder J, Horan C, et al:. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. Ultrasound Obstet Gynecol 10:1-6, 1997.
23. Fuchs-Young R, Magee DE, Cole HW, et al. Raloxifene is a tissue specific antiestrogen that blocks tamoxifen or estrogen stimulated uterotropic effects. Abstract presented at 77th Annual Meeting of the Endocrine Society, Washington, DC, 1995.
24. McDonnell DP, Clemm DL, Hermann T, et al: Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669, 1995.
25. Black LJ, Sato M, Rowley ER, et al: Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69, 1994.
26. Short L, Glasebrook AL, Adrian MD, et al: Distinct effects of selective estrogen receptor modulators on estrogen-dependent and estrogen-independent human breast cancer cell proliferation (Abstract). J Bone Miner Res 11:S482, 1996.
27. Delmas PD, Bjarnason NH, Mitlak BH: The effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647, 1997.
28. Goldstein SR: Uterine safety considerations for selective estrogen receptor modulators. Menopause 4:250, 1997.
29. Bryant HU, Glasebrook AL, Yang NN, et al: A pharmacologic review of Raloxifene. J Bone Miner Metab 14:1-9, 1996.
30. LaBrie F, Veilleux R, Fournier A: Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture. Mol Cell Endocrinol 58:207-211, 1988.
31. Walsh BW, et al: JAMA 279:1445-1451, 1998.